Related Experiment Video
Updated: May 12, 2026
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Fcγ receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective
Tongxin Wang1, Hanchao Li1, Li Zhu1
1Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Background:
To investigate whether Fcγ receptors (FcγRs) expression on peripheral blood monocytes predicts clinical response to etanercept in rheumatoid arthritis (RA).
Methods:
In this prospective cohort study, FcγRs expression on peripheral blood monocyte subsets was analyzed by flow cytometry. The primary outcome was the change in DAS28-CRP from baseline to week 12. The secondary outcome was the change in DAS28-ESR.
Results:
Following etanercept therapy, the proportion of FcγRI-positive monocytes and classical (CD14++CD16-) monocytes was reduced, while the proportion of non-classical (CD14+CD16++) monocytes was increased. Changes in intermediate monocytes (CD14++CD16+) were positively correlated with both DAS28-CRP change and DAS28-ESR change at week 24 after etanercept therapy. Patients with high intermediate (CD14++CD16+) monocytes showed significantly greater reductions in DAS28-CRP at week 12.
Conclusion:
Intermediate monocytes (CD14++CD16+) were correlated with improvements in DAS28-CRP achieved by week 12 following etanercept therapy. RA patients with low intermediate monocytes may derive less benefit from etanercept treatment.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...